Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Clinical Data
  • Novo Nordisk starts trialing lower maintenance doses of oral Wegovy
  • Clinical Data

Novo Nordisk starts trialing lower maintenance doses of oral Wegovy

BioSpace

The Phase 3 study is evaluating two doses of Novo's Wegovy pill in people with obesity or overweight in combination with a reduced-calorie diet and increased physical activity.

Metabolic & GLP-1

Read full story

pharminent August 21, 2026 (Last updated: August 23, 2026)

BioSpace

The Phase 3 study is evaluating two doses of Novo’s Wegovy pill in people with obesity or overweight in combination with a reduced-calorie diet and increased physical activity.

Metabolic & GLP-1

Read full story

Post navigation

Previous: How cost and perception could reshape the GLP-1 market
Next: Johnson & Johnson Wins EU Approval for Tecvayli-Daratumumab in Second-Line Myeloma

Related Stories

  • Clinical Data

Novartis hit as Lp(a) drug fails cardio outcomes trial

pharminent September 7, 2026
  • Clinical Data

Major trial of Roche Alzheimer’s drug kicks off in Europe

pharminent September 7, 2026
  • Clinical Data

AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study

pharminent September 4, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.